BofA’s Hartnett says concentrated U.S. stock returns are likely to persist
PURCHASE, N.Y. - Cognition Therapeutics, Inc. (NASDAQ: CGTX), a biopharmaceutical company focused on neurodegenerative disorders, announced results from its Phase 2 SHINE study of zervimesine in treating Alzheimer’s disease. The findings were presented at the AD/PD™ 2025 Alzheimer’s & Parkinson’s Diseases Conference in Vienna, Austria.
The study evaluated the effects of zervimesine on various biomarkers in patients with mild-to-moderate Alzheimer’s disease. Notably, participants who received zervimesine showed reductions in plasma biomarkers associated with Alzheimer’s disease compared to those who were given a placebo. This was particularly evident in a subgroup of patients with lower levels of a protein called p-Tau217, which is considered an indicator of Alzheimer’s pathology. InvestingPro analysis shows that while the company maintains a strong liquidity position with a current ratio of 2.65, it’s currently experiencing rapid cash burn, a critical factor for investors following clinical-stage biotech companies.
Significant decreases in glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) were observed in the zervimesine-treated group, suggesting reduced neuroinflammation and neurodegeneration. Additionally, levels of amyloid beta (Aβ) and p-Tau217 were lower after six months of treatment with zervimesine.
Dr. Mary Hamby, VP of research at Cognition, stated that the biomarker changes align with the cognitive improvements seen in the overall study population, with more pronounced effects in the low-p-Tau217 subgroup. These results support the understanding of zervimesine’s mechanism of action and its potential impact on the disease.
Cognition Therapeutics is also investigating zervimesine in other clinical programs, including dementia with Lewy bodies (DLB) and early Alzheimer’s disease. The company continues to explore the therapeutic’s interaction with the sigma-2 receptor, which is believed to regulate pathways impaired in neurodegenerative diseases.
These findings are based on a press release statement and have not been independently verified. The results of the Phase 2 SHINE study are preliminary, and further research is necessary to confirm the benefits and safety of zervimesine for Alzheimer’s disease treatment. With the next earnings report due on May 7, 2025, investors seeking deeper insights into CGTX’s financial health and growth prospects can access comprehensive analysis through InvestingPro, which offers exclusive access to 12+ additional ProTips and detailed financial metrics not available elsewhere.
In other recent news, Cognition Therapeutics reported a net loss of $34 million for 2024, consistent with the previous year, as the company focuses on advancing its Alzheimer’s and Dementia with Lewy Bodies (DLB) programs. The company has halted its Phase 2 study for dry acute macular degeneration to allocate resources towards Alzheimer’s and DLB, with plans to engage with the FDA for Phase 3 clinical protocols in the second quarter of 2025. H.C. Wainwright adjusted its price target for Cognition Therapeutics to $5, maintaining a Buy rating, while Brookline Capital Markets raised its target to $7, also reaffirming a Buy rating. Cognition Therapeutics is preparing to present its Phase 2 study results of the Alzheimer’s drug zervimesine at the AD/PD™ 2025 Conference, focusing on its impact on key Alzheimer’s-related proteins. The company aims to extend its cash runway into late 2025, supported by $12.8 million raised through an ATM facility, and is seeking partnerships for further development. Cognition Therapeutics’ research and development expenses were $41.7 million, up from the previous year, while grant income fell short of expectations. The company is confident about regaining NASDAQ compliance by September 2025 and is actively pursuing strategic partnerships to advance its clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.